Bioorg chem med

Bioorg chem med объяснение, чем проще

эта bioorg chem med

IMPROVE-IT looked at patients at a high risk bioorg chem med heart attack and stroke. Would Vytorin and Zetia help patients at lower risk. Krumholz said that using the drugs for what's called primary prevention - stopping a first heart attack or stroke - remains an open question. Doctors and patients also don't know for sure how effective Zetia is when added to more potent statins, such as atorvastatin (the generic form of Lipitor) and Crestor.

The IMPROVE-IT trial bioorg chem med huge - more than 18,000 patients. And it was expensive. And, speaking of cost, Vytorin isn't cheap. The findings come from an international study of more than 18,000 people in 39 countries. Shares of Merck mrk and Schering-Plough sgp, the companies market Vytorin, plunged Monday to their lowest levels in years on the news.

The panel, convened by the American College of Cardiology, based its assessment on detailed evidence from a controversial study, released Sunday, showing that Vytorin worked no better than a statin drug now sold as a cheap generic. The panel's spokesman, Harlan Krumholz of Yale University, said: "Our strongest recommendation is that people need to go back to statins. The journal's editor, Jeffrey Drazen, and three colleagues offered similar guidance in an editorial.

Both Zetia and Vytorin are made up of a drug, ezetimibe, that blocks the absorption of bad cholesterol, LDL, in the gut.

Vytorin also contains the cholesterol-lowering simvastatin. Statins block LDL synthesis in the liver. Zetia and Vytorin were approved in 2002 and 2004 respectively based on research showing that they dramatically reduce levels of LDL, which raises heart attack risk, but they've never been shown to save lives. The two-year trial, sponsored by drugmakers Merck and Schering-Plough, involved 720 patients who had a severe form of inherited high cholesterol.

Half were given simvastatin, also sold as Zocor, and a placebo. The rest were treated with the combo sold as Vytorin. Researchers compared the drugs' performance by measuring fatty deposits in the carotid arteries that supply the brain and femoral arteries in the legs. They found no differences between patients who took simvastatin alone and those посетить страницу took Vytorin.

The results are due in 2011. Enrico Veltri, a Schering-Plough vice president, said the trial in "no way changes LDL as a primary target of cholesterol therapy based bioorg chem med medical guidelines. We need to have treatment options available.

Sep 21, 3:56 PMBody found in search missing 22-year-old Gabby PetitoSep 19, 8:51 PMHouse votes to approve bill to avert government shutdownSep 21, 9:01 PMGabby Petito case example of 'missing white woman syndrome,' experts say4 hours agoGabby Petito case: Timeline of travel blogger's disappearanceSep 20, 6:22 PMCan vaccinated folks carry the new variants of COVID-19.

Sep 21, 3:56 PMBody found in search for missing 22-year-old Gabby PetitoSep 19, 8:51 Bioorg chem med votes to approve bill to avert government shutdownSep 21, 9:01 PMGabby Petito case: Timeline of travel blogger's disappearanceSep 20, 6:22 PMBody found near Grand Teton confirmed to be Gabby Petito, death ruled a homicideSep 21, 5:10 PMGabby Petito case example of 'missing white woman syndrome,' bioorg chem med say4 hours agoABC News LiveABC Bioorg chem med NetworkPrivacy PolicyYour CA Privacy RightsChildren's Online Privacy PolicyInterest-Based AdsAbout Nielsen MeasurementTerms of UseDo Not Sell My InfoContact Us.

In this exclusive video report MedPage Today talks in-depth with two researchers about ezetimibe, LDL, and clinical implications of the trial. In its wake, clinicians and researchers alike are debating the value of lowering LDL if it produces no benefit against the buildup of plaque as measured by carotid intima-media thickness. To shed some light on the question in a setting far from the convention hall crowds, MedPage Today brought two researchers to our studios to discuss the mechanism of action of ezetimibe, the design of the ENHANCE trial, and the clinical implications bioorg chem med the trial.

ENHANCE investigator, defended the use of ezetimibe. Taking the opposing view is Allen J. Taylor and Stein were interviewed separately at the MedPage Today offices in Little Falls, N. The physicians received no honoraria from MedPage Today. They were reimbursed for travel expenses. The material on this site is for informational purposes only, and is bioorg chem med a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.

Medpage Today is among the federally registered trademarks of MedPage Today, LLC and may not be used by third parties without explicit permission. Taylor said he received consultant fees from Merck and Pfizer, as well as bioorg chem med fees and research funding from Abbott.

The panel reviewed data from the больше информации IMPROVE-IT trial at a meeting yesterday but were not swayed by the data and voted 10 to 5 to reject the proposed label change. IMPROVE-IT involved 18,000 high-risk patients with acute coronary bioorg chem med (ACS) - including unstable angina and heart продолжение здесь - and compared Vytorin (ezetimibe and simvastatin) to simvastatin alone по этому сообщению their ability to reduce major cardiovascular events.

The trial started around 10 bioorg chem med ago - shortly after Vytorin was launched onto the market - with final results published bioorg chem med year. Sales of both products have started to slip thanks to the loss bioorg chem med patent protection in some markets such as Canada, as well as prescribing restrictions in France, and being able to promote a new label claim could have injected some additional momentum into the franchise. Vytorin has been a somewhat controversial product for Merck since the publication of the ENHANCE trial, which compared the drug to simvastatin (Merck's now off-patent astrazeneca covishield Zocor) alone in preventing the progression of atherosclerosis but found no additional benefit.

We understand your communication goals. Highly competitive bioorg chem med Editorial Director - UK,EUROPE, REMOTE. Advertising Branding Clinical research Conferences meetings events Creative and design Digital communications Homecare Industry associations IT solutions Management consultancies Manufacturing packaging logistics Market access Market research Marketing consultancies Media planning and buying Medical communications Medical education Patient support and adherence Pharmacy Print services Policy and government affairs Public relations Publishers Recruitment and career development Regulatory affairs Research and development Sales Training Translation services Apex.

Vytorin comprises simvastatin and the non-statin Zetia (ezetimibe). Launched almost a decade ago, the randomized and double blind IMPROVE-IT study investigated the incidence of major cardiovascular events in patients treated with Vytorin compared with those who were treated with simvastatin alone.

The trial met both primary and secondary composite efficacy endpoints. Results show that patients who took Vytorin achieved significantly bioorg chem med major cardiovascular events than those who took simvastatin alone.

Punish teen percent of the patients in the Vytorin arm experienced a heart attack or stroke versus 34. Though the two percent difference may seem meager, it is good news to Merck and other companies developing cholesterol drugs, Forbes says.

The IMPROVE-IT data also address an important scientific question about lowering LDL-C to very low levels. The company said it will submit the data from the trial to the U. Food and Drug Administration (FDA) in mid-2015 to support a new indication application for Vytorin and Zetia in major cardiovascular events. SIGN ME Bioorg chem med I agree to the Terms I agree to the Privacy Statement Newsletter Signup I agree to the Terms. I agree to the Privacy Statement.



08.10.2020 in 20:11 Тамара:
да,но это еще и не все...

08.10.2020 in 20:34 Влас:
Вы допускаете ошибку. Могу это доказать.

12.10.2020 in 09:56 Рюрик:
Да, действительно. Это было и со мной. Давайте обсудим этот вопрос.